Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology
[next]
(Date:5/14/2008)...y 14 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC Bu...d quarter ended March 31, 2008,with net earnings o... of,$2,699,000. This compares to net earnings of $...f $2,990,000 for the third quarter of last year. F...d net earnings of $475,000,or $0.17 per diluted s...
(Date:5/14/2008)...y to survive using chemoradiation, and new treatme...althDay News) -- Tonsil and tongue cancers linked ...to current chemotherapy and radiation treatments, ...actor called EGFR are the least responsive and mos...f Michigan Comprehensive Cancer Center researchers...
(Date:5/14/2008)...s work well, too, giving patients options , ...rgest study of its kind supports the use of a popu...ts a cocktail of two classes of drugs is a good al... as well, said study lead author Dr. Sharon Riddle...ty of Pittsburgh. , "It,s not like 10 years a...
(Date:5/14/2008)...ight add to traditional risk factors , ,... four offbeat biomarkers accurately predicted the ...dy of older Swedish men, researchers report. , ... that might one day lead to widespread medical use...ed risk factors such as high blood pressure and ch...
Breaking Medicine News(10 mins):Health News:Biotel Announces Profitable Third Quarter Ended March 31, 2008 2Health News:HPV Tied to Better Tongue, Tonsil Cancer Outcomes 2Health News:Study Supports Popular HIV Drug Regimen 2Health News:Study Supports Popular HIV Drug Regimen 3Health News:Biomarkers Predict Heart Deaths 2Health News:Biomarkers Predict Heart Deaths 3
...al Alcoholism: Clinical and Experimental Research ...f smell. Researchers from the University Clinics o...olics and 30 healthy people who were matched for a...' Sticks", which are pen-like devices that dispens...
...mmatory condition of the bladder wall. It typicall...so affect men. Investigators are testing the bacte...ier studies was found to be effective in treating ...ions into the bladders of patients through a cathe...
...n a recent seminar organised by Guru Gobind Singh ...utation', spoke about the comapny's plan of forayi...r products would create stiff competition for the ...er cent market share. The company plans to market ...
...his colleagues are enthused by their finding of a ...ying into human cells. This blocker, in its initia...smission of HIV between monkeys. The new study has... that hobble viruses - could act as shields agains...
Other Medicine News:
...r mini horizontal gel electrophoresis system is de...estriction fragments in agarose gels. This system ...hern or Northern blotting of high quality. Complet..., 2 x Gel Maker Stands, (4) 52 x 60 mm Trays, (2) ...
...ni-Chameleon has a centimeter ruler etched into th...ncludes apparatus, connecting cables, three 7x10 c... and three 14-well combs. The Chameleon can accomo...electrophoresis of a maximum of 120 samples with a...
...ystem™ consists of a Separation-Control unit...elopment Unit for gel staining. The optional Phast...mi-dry blotting unit. Electrophoresis is performed...mperatures accurately from 0 to +70 C. Multi-step ...
...A 2000 apparatus and ready-to-use gels are the key...cleic acids by submerged gel electrophoresis. We p...ffering full compatibility and optimal performance...0 and a unique staining tray, the system includes ...
Medicine Products:
(Date:5/13/2008)... with XIENCE V in SPIRIT III Trial Experience Bett...ent Thrombosis than Patients ... /- Long-term data,presente...al, Abbott,s U.S.,pivotal trial studying the XIENC...demonstrated that XIENCE V continues to deliver cl...
(Date:5/12/2008)...SCO, Calif., May 12 /- Napo...unces that it presented a,poster in collaboration ...t,of a patient reported outcomes questionnaire foc...) aspects of chronic diarrhea in persons living wi...Pharmacoeconomics and,Outcomes Research (ISPOR) An...
(Date:5/12/2008).../- GeoVax Labs, Inc. (OTC,B...accine development,company, announced today that i...hase agreement with Fusion Capital Fund II, LLC, a...ny may sell up to $10 million of its common stock ...h period after the Securities and,Exchange Commiss...
(Date:5/12/2008)...May 12 /- Arbios Systems, I...t the Company has received,approval from the U.S. ...gational Device Exemption ("IDE") to begin the piv...rporeal (outside the body) liver assist,device for...ing from,chronic liver disease., "We are pleased ...
Breaking Medicine Technology:XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5Napo Presents at ISPOR Meeting in Toronto 2GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development 3001 1Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development 3001 2Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development 3001 3Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development 3001 4Ceremeds OSTENE 28R 29 Stops Bone Bleeding Without Added Risk of Surgical Infection New Study Finds 1316 1Ceremeds OSTENE 28R 29 Stops Bone Bleeding Without Added Risk of Surgical Infection New Study Finds 1316 2Ceremeds OSTENE 28R 29 Stops Bone Bleeding Without Added Risk of Surgical Infection New Study Finds 1316 3Pharmaxis Investor Conference Call 2999 1Material Technologies Holds First Electrochemical Fatigue Sensor Training for Private Inspection Firms 2114 1Material Technologies Holds First Electrochemical Fatigue Sensor Training for Private Inspection Firms 2114 2Material Technologies Holds First Electrochemical Fatigue Sensor Training for Private Inspection Firms 2114 3
...- Arrowhead Research,Corporation (NASDAQ: ARWR) an...idiary Calando Pharmaceuticals, Inc. of a study,de...iRNA sequence,selected as the therapeutic componen... paper, entitled "Potent siRNA Inhibitors of Ribon...feration In vitro and In,vivo", was published in C...
...laque Formation, ANNAPOLIS, Md., April 03, 2007 /P...nse company specializing in the development,and co... chemical,and biological terrorism, announced toda...esterase (rBChE) research program were,recently pr...heimer,s and Parkinson,s Diseases in Salzburg, Aus...
Other Medicine Technology:Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6